Heart and Vessels

, Volume 19, Issue 3, pp 137–143 | Cite as

Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline

  • Mikio Hiramatsu
  • Long-Mei Wu
  • Yuji Hirano
  • Seiko Kawano
  • Tetsushi Furukawa
  • Masayasu Hiraoka
ORIGINAL ARTICLE

Abstract

A Na+-channel blocker, cibenzoline, blocks the delayed rectifier potassium current (I k), but its detailed action on the rapidly activating component (I kr) of I k encoded by the human ether-a-go-go-related gene (HERG) has not been clarified. We examined the effects of cibenzoline on stably expressed HERG current in HEK293 cells recorded by the patch-clamp technique of whole-cell configuration. Cibenzoline blocked HERG current expressed in HEK293 cells with IC50 = 3.7 ± 0.963 µM and Hill coefficient = 0.74 ± 0.12. Voltage-depended activation was shifted in a negative direction by cibenzoline. No block or minor block was induced at test depolarization of −40 to −30 mV, and the block increased with depolarization reaching a plateau at 0 mV without a further increase at positive voltages. Voltage-dependent activation of HERG currents became faster at negative test voltages but there were no changes at positive voltages after cibenzoline. No frequency-dependent block of HERG tail current by cibenzoline after equilibration was noted between 1.33 and 0.2 Hz. Steady-state inactivation of the HERG current was shifted in a negative direction by ∼8 mV but the time constants of fast inactivation were little affected by cibenzoline. Cibenzoline blocks the I kr-like current reconstituted by HERG clone transfection with an IC50 value comparable to therapeutic concentrations. Cibenzoline has a preferential affinity, at least, to the open state of the HERG channel with a rapid access to the binding site.

Key words

Rapidly activating component of potassium current HERG channel Open state of channel Action potential duration QT prolongation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Tokyo 2004

Authors and Affiliations

  • Mikio Hiramatsu
    • 1
  • Long-Mei Wu
    • 1
  • Yuji Hirano
    • 1
  • Seiko Kawano
    • 1
  • Tetsushi Furukawa
    • 2
  • Masayasu Hiraoka
    • 1
  1. 1.Department of Cardiovascular Disease, Medical Research InstituteTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Department of Clinical Pharmacology, Medical Research InstituteTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations